Regeneron Adopts Veeva Vault CRM for AI-Powered Commercial Evidence
Event summary
- Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally as of August 25, 2026.
- Veeva Vault CRM will generate Commercial Evidence from AI-powered field engagement for Regeneron.
- Ryan Steinberger, Regeneron's EVP and Chief Digital and Technology Officer, highlighted the move as a way to give commercial teams a more connected platform.
- Veeva Vault CRM is part of the Vault CRM Suite, which provides the technology foundation for commercial execution.
The big picture
This adoption underscores the growing trend of biopharma companies leveraging AI and digital transformation to enhance commercial execution. Regeneron's move to Veeva Vault CRM highlights the strategic importance of generating actionable insights from field engagement to improve patient access to medicines. The partnership also reflects the broader industry shift towards data-driven decision-making in life sciences.
What we're watching
- AI Integration
- How Veeva's AI-powered field engagement will impact Regeneron's commercial strategy and treatment adoption.
- Commercial Evidence
- Whether the Commercial Evidence generated by Vault CRM will uncover significant barriers to treatment adoption.
- Strategic Partnership
- The pace at which Veeva and Regeneron will expand their strategic partnership beyond Vault CRM.